Adrenoleukodystrophy (ALD)- Epidemiology Forecast to 2028

Adrenoleukodystrophy (ALD)- Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Adrenoleukodystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2016-2028

Adrenoleukodystrophy Epidemiology
The Adrenoleukodystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Adrenoleukodystrophy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adrenoleukodystrophy Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, diagnosed prevalence of ALD by clinical manifestations (cerebral ALD, Adrenomyleoneuropathy and Addisons disease), diagnosed prevalence of CALD by segmentation (childhood, adolescent, adult ALD)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to , total prevalent cases of Adrenoleukodystrophy in 7 major markets are found out to be 26,866 in 2016.

Report Scope
The report covers detailed overview of Adrenoleukodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The report provides the insight about the historical and forecasted patient pool of Adrenoleukodystrophy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Report assesses the disease risk and burden and highlights the unmet needs of the disease
The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report provides the segmentation of the disease epidemiology by Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM

Key strengths
10 Year Forecast of Adrenoleukodystrophy epidemiology
7MM Coverage
Total Prevalent Cases of Adrenoleukodystrophy
Prevalent Cases according to segmentation: Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM
Diagnosed cases of Adrenoleukodystrophy

Key assessments
Patient Segmentation
Disease Risk & Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
1. Key Insights
2. Disease Background and Overview: Adrenoleukodystrophy (ALD)
2.1. Introduction
2.2. Clinical aspects of ALD
2.3. Disease Causes
2.4. Inheritance pattern of ALD
2.5. ALD-Symptoms
2.6. Pathogenesis
2.7. ALD Diagnosis
2.8. X-ALD Newborn Screening
2.9. Tools for evaluating Cerebral X-ALD
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Disease Definition
3.3. Population and Forecast Parameters
4. 7MM Prevalent Population of Adrenoleukodystophy (ALD)
5. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD)
5.1. United States
5.1.1. Prevalent Population of Adrenoleukodystrophy in United States
5.1.2. Diagnosed Prevalence of ALD by Clinical Manifestation in United States
5.1.3. Diagnosed Prevalence of CALD by Segmentation in United States
5.2. Germany
5.2.1. Prevalent Population of Adrenoleukodystrophy in Germany
5.2.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany
5.2.3. Diagnosed Prevalence of CALD by Segmentation in Germany
5.3. France
5.3.1. Prevalent Population of Adrenoleukodystrophy in France
5.3.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the France
5.3.3. Diagnosed Prevalence of CALD by Segmentation in France
5.4. Italy
5.4.1. Prevalent Population of Adrenoleukodystrophy in Italy
5.4.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy
5.4.3. Diagnosed Prevalence of CALD by Segmentation in Italy
5.5. Spain
5.5.1. Prevalent Population of Adrenoleukodystrophy in Spain
5.5.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain
5.5.3. Diagnosed Prevalence of CALD by Segmentation in Spain
5.6. United Kingdom
5.6.1. Prevalent Population of Adrenoleukodystrophy in United Kingdom
5.6.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the United Kingdom
5.6.3. Diagnosed Prevalence of CALD by Segmentation in United Kingdom
5.7. Japan
5.7.1. Prevalent Population of Adrenoleukodystrophy in Japan
5.7.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan
5.7.3. Diagnosed Prevalence of CALD by Segmentation in Japan
6. Appendix
7. Report Methodology
7.1. Sources used
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight

List Of Tables

Table 1: X-ALD Phenotypes in Males
Table 2: Phenotype in Female X-ALD carriers
Table 3: The X-ALD Phenotypes
Table 4: MRI Severity Scale
Table 5: MRI Severity Rating (Loes Score)
Table 6: Neurological Function Score (NFS Score)
Table 7: X-linked Adrenoleukodystrophy- Disability Rating Scale (ALD-DRS)
Table 8: Prevalent Population of Adrenoleukodystophy in the 7MM (2016-2028)
Table 9: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028)
Table 10: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028)
Table 11: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028)
Table 12: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028)
Table 13: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028)
Table 14: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028)
Table 15: Prevalent Population of Adrenoleukodystrophy in France (2016-2028)
Table 16: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028)
Table 17: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028)
Table 18: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028)
Table 19: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028)
Table 20: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028)
Table 21: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028)
Table 22: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028)
Table 23: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028)
Table 24: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028)
Table 25: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028)
Table 26: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028)
Table 27: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028)
Table 28: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028)
Table 29: Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028)

List Of Figures

Figure 1: Evolution of Phenotypes in X-ALD
Figure 2: Clinical Spectrum of X-ALD
Figure 3: Inheritance spectrum of X-ALD
Figure 4: Pathogenesis of VLCFA
Figure 5: Principles of ALD 3-tier screening
Figure 6: Diagnostic algorithm for diagnosis of adrenoleukodystrophy
Figure 7: Prevalent Population of X-Adrenoleukodystophy in the 7MM (2016-2028)
Figure 8: Prevalent Population of Adrenoleukodystrophy in United States (2016-2028)
Figure 9: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2028)
Figure 10: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2028)
Figure 11: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2028)
Figure 12: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2028)
Figure 13: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2028)
Figure 14: Prevalent Population of Adrenoleukodystrophy in France (2016-2028)
Figure 15: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2028)
Figure 16: Diagnosed Prevalence of CALD by Segmentation in France (2016-2028)
Figure 17: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2028)
Figure 18: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2028)
Figure 19: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2028)
Figure 20: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2028)
Figure 21: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2028)
Figure 22: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2028)
Figure 23: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2028)
Figure 24: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2028)
Figure 25: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2028)
Figure 26: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2028)
Figure 27: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2028)
Figure 28 Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2028)

Global Adrenoleukodystrophy Drugs Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Adrenoleukodystrophy Drugs is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end

USD 4000 View Report

North America Adrenoleukodystrophy Drugs Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Adrenoleukodystrophy Drugs market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million USD by

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available